Abstract:Immunostimulatory cues play an important role in priming antitumor immunity and promoting the efficacy of subunit cancer vaccines. However, the clinical use of many immunostimulatory agents is often hampered by their inefficient in vivo delivery which may decrease immune response to the vaccination. To promote vaccine efficacy, we develop vaccine formulations which integrate three key elements: (1) a nano-adjuvant formulated by conjugating an agonistic anti-CD40 monoclonal antibody (αCD40) to the surface of a polyIC-loaded lipid nanoparticle, (2) a peptide amphiphile containing an optimized CD8 + T-cell epitope that derived from a melanoma antigen gp100, (3) an agonistic anti-4-1BB monoclonal antibody (α4-1BB) that boosts the efficacy of vaccinations. In a syngeneic mouse model of melanoma, the vaccine formulations enhanced innate immunity and activated multiple innate immune signaling pathways within draining lymph nodes, as well as promoted antigen-specific immune responses and reduced immunosuppression in the tumor microenvironment, leading to profound tumor growth inhibition and prolonged survival. Thus, our vaccine formulations represent an attractive strategy to stimulate antitumor immunity and control tumor progression. Statement of significance The clinical use of many immunostimulatory agents is often hampered by their inefficient in vivo delivery which may decrease immune response to the vaccination. To promote the antitumor immunity of subunit vaccines, we develop novel vaccine formulations that integrate multifunctional modalities including (1) a nano-adjuvant containing anti-CD40 monoclonal antibody (αCD40) and TLR3 agonist which activate innate immunity through diverse signaling pathways, (2) a peptide amphiphile containing an optimized CD8 + T-cell epitope from tumor antigen, (3) an anti-4-1BB monoclonal antibody (α4-1BB) that boosts the efficacy of vaccinations. In this study, our vaccine formulations stimulate superior antitumor immunity and control tumor progression. The above nano-engineered platform and immunogenic biomacromolecules can be further applied to other T-cell-inducing vaccines.

Immunogenicity regulation of genetically engineered vaccine and its potential in tumor treatment

Genetically engineered T cells for cancer immunotherapy

Tumor Vaccines: Unleashing the Power of the Immune System to Fight Cancer

Combination of GNRs-PEI/cGAMP-laden Macrophages-Based Photothermal Induced in Situ Tumor Vaccines and Immune Checkpoint Blockade for Synergistic Anti-Tumor Immunotherapy.

Advances of mRNA vaccine in tumor: a maze of opportunities and challenges

Advanced Nano-Based Strategies for Mrna Tumor Vaccine

A recent perspective on designing tumor vaccines for tumor immunology

mRNA vaccines in tumor targeted therapy: mechanism, clinical application, and development trends

Components, Formulations, Deliveries, and Combinations of Tumor Vaccines

Advances and prospects of mRNA vaccines in cancer immunotherapy

Genetic engineering strategies to enhance antitumor reactivity and reduce alloreactivity for allogeneic cell-based cancer therapy

Cancer Vaccines Designed Based the Nanoparticle and Tumor Cells for the Treatment of Tumors: A Perspective

Biomimetic and bioinspired nano‐platforms for cancer vaccine development

Advances in Cancer Vaccine Research

The Mechanism of Stimulating and Mobilizing the Immune System Enhancing the Anti-Tumor Immunity

mRNA vaccine development and applications: A special focus on tumors (Review)

Engineering customized nanovaccines for enhanced cancer immunotherapy

Classification and research status of tumor vaccines

Nano-adjuvants and immune agonists promote antitumor immunity of peptide amphiphiles

Potentialities and Challenges of mRNA Vaccine in Cancer Immunotherapy

Research progress of nanovaccine in anti-tumor immunotherapy